President Trump announced nine more companies joining TrumpRx, aiming for U.S.-Europe drug price parity using tariffs as leverage. TrumpRx will offer future drug releases at most-favored-nation ...
On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain foreign biotechnology companies viewed as national security risks. The measure ...
Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
BioMarin Pharmaceuticals entered into a definitive agreement to acquire Amicus Therapeutics to expand its position in rare diseases, increase revenue growth, and strengthen the co ...
Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
Four GOP members of the House of Representatives joined with House Democrats to force a vote on extending tax credits that ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...
Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...
The Biosecure Act aims to prevent federal funding to Chinese biotech companies labeled "of concern" by the Office of Management and Budget or the Department of Defense. A political shift in the House ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results